Adaptive Biotechnologies Corporation(ADPT)

Biotechnology · Seattle, WA

$29.84+1.49 (+5.26%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T11:40:29.025Z.

Stored calculation inputs

Calculation as of: 2026-10-06T11:40:29.025Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 4,775,712,960
Total debt · period ending 2026-06-30: 410,499,000
Cash · period ending 2026-06-30: 169,873,000
TTM free cash flow · period ending 2026-06-30: -24,034,000

FMP input reference: 8b4a3eec411172ef5ea6343195523a59a16bbab67eb0b09a3c3cdf82258b1615

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

EV/FCF Ratio

ADPT EV/FCF Ratio Chart

N/A

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2020-05-12.

ADPT EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

EV/FCF RATIO AVG TTM

N/A

EV/FCF RATIO AVG 3Y

N/A

EV/FCF RATIO AVG 5Y

N/A

EV/FCF RATIO AVG 10Y

N/A

EV/FCF RATIO AVG 15Y

N/A

EV/FCF RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

ADPT Competitors' EV/FCF Ratio

ADPT

Adaptive Biotechnologies Corporation

Current

Market Cap

$4.78B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DFTX

Definium Therapeutics, Inc.

vs ADPT

Market Cap

$4.81B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DNTH

Dianthus Therapeutics, Inc.

vs ADPT

Market Cap

$4.92B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BLLN

BillionToOne, Inc.

vs ADPT

Market Cap

$5.02B

EV/FCF Ratio

139.01x

TTM Avg

178.16x

3Y Avg

178.16x

5Y Avg

178.16x

ERAS

Erasca, Inc.

vs ADPT

Market Cap

$5.11B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SRRK

Scholar Rock Holding Corporation

vs ADPT

Market Cap

$5.20B

EV/FCF Ratio

N/A

TTM Avg

29.52x

3Y Avg

29.52x

5Y Avg

29.52x

MMSI

Merit Medical Systems, Inc.

vs ADPT

Market Cap

$5.20B

EV/FCF Ratio

27.39x

TTM Avg

27.85x

3Y Avg

42.08x

5Y Avg

46.24x

EWTX

Edgewise Therapeutics, Inc.

vs ADPT

Market Cap

$4.34B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COGT

Cogent Biosciences, Inc.

vs ADPT

Market Cap

$5.27B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ABCL

AbCellera Biologics Inc.

vs ADPT

Market Cap

$4.21B

EV/FCF Ratio

N/A

TTM Avg

17.56x

3Y Avg

217.22x

5Y Avg

217.22x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Adaptive Biotechnologies Corporation (ADPT)	$4.78B	N/A	N/A	N/A	N/A
Definium Therapeutics, Inc. (DFTX)vs ›	$4.81B	N/A	N/A	N/A	N/A
Dianthus Therapeutics, Inc. (DNTH)vs ›	$4.92B	N/A	N/A	N/A	N/A
BillionToOne, Inc. (BLLN)vs ›	$5.02B	139.01x	178.16x	178.16x	178.16x
Erasca, Inc. (ERAS)vs ›	$5.11B	N/A	N/A	N/A	N/A
Scholar Rock Holding Corporation (SRRK)vs ›	$5.20B	N/A	29.52x	29.52x	29.52x
Merit Medical Systems, Inc. (MMSI)vs ›	$5.20B	27.39x	27.85x	42.08x	46.24x
Edgewise Therapeutics, Inc. (EWTX)vs ›	$4.34B	N/A	N/A	N/A	N/A
Cogent Biosciences, Inc. (COGT)vs ›	$5.27B	N/A	N/A	N/A	N/A
AbCellera Biologics Inc. (ABCL)vs ›	$4.21B	N/A	17.56x	217.22x	217.22x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

ADPT EV/FCF Ratio History

DATE	EV/FCF RATIO
2020-05-12	24.07x
2020-05-11	24.11x
2020-05-08	22.78x
2020-05-07	22.79x
2020-05-06	21.38x
2020-05-05	20.84x
2020-05-04	20.48x
2020-05-01	19.24x
2020-04-30	20.20x
2020-04-29	20.52x
2020-04-28	20.18x
2020-04-27	20.20x
2020-04-24	18.33x
2020-04-23	17.95x
2020-04-22	19.10x
2020-04-21	18.68x
2020-04-20	18.61x
2020-04-17	17.61x
2020-04-16	17.79x
2020-04-15	17.90x
2020-04-14	17.73x
2020-04-13	16.91x
2020-04-09	16.20x
2020-04-08	15.72x
2020-04-07	15.67x
2020-04-06	17.69x
2020-04-03	16.17x
2020-04-02	17.71x
2020-04-01	17.31x
2020-03-31	17.49x
2020-03-30	17.06x
2020-03-27	15.95x
2020-03-26	16.46x
2020-03-25	15.89x
2020-03-24	14.80x
2020-03-23	14.21x
2020-03-20	14.38x
2020-03-19	14.14x
2020-03-18	11.69x
2020-03-17	11.23x
2020-03-16	10.55x
2020-03-13	12.31x
2020-03-12	11.02x
2020-03-11	13.48x
2020-03-10	15.69x
2020-03-09	15.45x
2020-03-06	17.01x
2020-03-05	17.32x
2020-03-04	18.09x
2020-03-03	16.17x
2020-03-02	16.86x
2020-02-28	17.69x
2020-02-27	17.83x
2020-02-26	16.86x
2020-02-25	17.06x
2020-02-24	17.54x
2020-02-21	19.46x
2020-02-20	19.26x
2020-02-19	19.09x
2020-02-18	18.07x
2020-02-14	17.91x
2020-02-13	18.05x
2020-02-12	17.87x
2020-02-11	17.90x
2020-02-10	17.83x
2020-02-07	18.40x
2020-02-06	17.91x
2020-02-05	17.11x
2020-02-04	16.71x
2020-02-03	17.06x
2020-01-31	17.01x
2020-01-30	17.54x
2020-01-29	17.61x
2020-01-28	17.69x
2020-01-27	17.33x
2020-01-24	17.38x
2020-01-23	15.25x
2020-01-22	15.44x
2020-01-21	15.22x
2020-01-17	16.03x
2020-01-16	15.55x
2020-01-15	16.84x
2020-01-14	16.60x
2020-01-13	17.01x
2020-01-10	16.98x
2020-01-09	17.09x
2020-01-08	17.06x
2020-01-07	16.86x
2020-01-06	16.83x
2020-01-03	16.95x
2020-01-02	16.70x
2019-12-31	17.02x
2019-12-30	16.46x
2019-12-27	16.64x
2019-12-26	16.84x
2019-12-24	17.06x
2019-12-23	18.30x
2019-12-20	18.46x
2019-12-19	17.20x
2019-12-18	17.61x
2019-12-17	16.69x
2019-12-16	17.19x
2019-12-13	17.18x
2019-12-12	18.03x
2019-12-11	17.25x
2019-12-10	16.31x
2019-12-09	16.65x
2019-12-06	16.52x
2019-12-05	16.69x
2019-12-04	15.43x
2019-12-03	15.32x
2019-12-02	15.62x
2019-11-29	15.44x
2019-11-27	15.81x
2019-11-26	16.00x
2019-11-25	16.90x
2019-11-22	16.28x
2019-11-21	15.83x
2019-11-20	16.34x
2019-11-19	16.40x
2019-11-18	17.14x
2019-11-15	16.20x
2019-11-14	15.50x
2019-11-13	15.49x
2019-11-12	14.58x
2019-11-11	14.56x
2019-11-08	14.18x
2019-11-07	13.68x
2019-11-06	13.76x
2019-11-05	14.40x
2019-11-04	15.68x
2019-11-01	14.45x
2019-10-31	13.39x
2019-10-30	13.39x
2019-10-29	13.46x
2019-10-28	13.40x
2019-10-25	13.15x
2019-10-24	13.35x
2019-10-23	12.60x
2019-10-22	13.10x
2019-10-21	13.55x
2019-10-18	15.06x
2019-10-17	15.97x
2019-10-16	15.50x
2019-10-15	15.38x
2019-10-14	13.94x
2019-10-11	14.15x
2019-10-10	14.76x
2019-10-09	14.86x
2019-10-08	15.23x
2019-10-07	16.90x
2019-10-04	16.29x
2019-10-03	15.91x
2019-10-02	15.41x
2019-10-01	15.50x
2019-09-30	15.91x
2019-09-27	15.60x
2019-09-26	16.58x
2019-09-25	18.02x
2019-09-24	19.29x
2019-09-23	20.93x
2019-09-20	20.76x
2019-09-19	20.14x
2019-09-18	20.44x
2019-09-17	20.83x
2019-09-16	21.45x
2019-09-13	22.32x
2019-09-12	20.53x
2019-09-11	21.57x
2019-09-10	21.31x
2019-09-09	20.38x
2019-09-06	22.65x
2019-09-05	23.05x
2019-09-04	27.70x
2019-09-03	26.56x
2019-08-30	26.31x
2019-08-29	25.92x
2019-08-28	24.52x
2019-08-27	22.99x
2019-08-26	22.84x
2019-08-23	22.27x
2019-08-22	23.63x
2019-08-21	24.26x
2019-08-20	23.28x
2019-08-19	23.82x
2019-08-16	23.83x
2019-08-15	24.72x
2019-08-14	22.47x
2019-08-13	21.02x
2019-08-12	20.49x
2019-08-09	20.30x
2019-08-08	19.34x
2019-08-07	18.99x
2019-08-06	17.68x
2019-08-05	17.06x
2019-08-02	18.16x
2019-08-01	18.81x
2019-07-31	18.77x
2019-07-30	17.94x
2019-07-29	18.37x
2019-07-26	19.32x
2019-07-25	19.59x
2019-07-24	19.68x
2019-07-23	19.68x
2019-07-22	19.12x
2019-07-19	18.76x
2019-07-18	18.50x
2019-07-17	18.54x
2019-07-16	18.82x
2019-07-15	18.56x
2019-07-12	18.99x
2019-07-11	18.31x
2019-07-10	18.34x
2019-07-09	17.99x
2019-07-08	18.25x
2019-07-05	19.74x
2019-07-03	19.07x
2019-07-02	18.94x
2019-07-01	19.54x
2019-06-28	23.63x
2019-06-27	19.64x

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.

Seattle, WA

624 employees

www.adaptivebiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Chad Robins

View full financials

EV/FCF Ratio: N/A

ADPT EV/FCF Ratio Chart

ADPT EV/FCF Ratio Metrics

ADPT Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

ADPT EV/FCF Ratio History

Related Metrics

EV/FCF Ratio: N/A

ADPT EV/FCF Ratio Chart

ADPT EV/FCF Ratio Metrics

ADPT Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

ADPT EV/FCF Ratio History

Related Metrics